zoledronic acid has been researched along with Graft-Versus-Host Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chae, YS; Kim, JG; Kim, SN; Kim, YJ; Lee, SJ; Moon, JH; Sohn, SK | 1 |
| Fazzi, R; Galimberti, S; Pacini, S; Petrini, I; Petrini, M; Trombi, L | 1 |
1 trial(s) available for zoledronic acid and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
Topics: Adolescent; Adult; Aged; Bone Density; Bone Density Conservation Agents; Chronic Disease; Diphosphonates; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Pilot Projects; Stem Cell Transplantation; Steroids; Transplantation, Homologous; Zoledronic Acid | 2009 |
1 other study(ies) available for zoledronic acid and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells.
Topics: Adolescent; Adult; Bone Density Conservation Agents; Cytotoxicity, Immunologic; Diphosphonates; Female; Graft vs Host Disease; Humans; Imidazoles; Interleukin-2; Killer Cells, Natural; Male; Mesenchymal Stem Cells; Middle Aged; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Cytotoxic; Young Adult; Zoledronic Acid | 2009 |